Bicara Therapeutics Inc. has recently been added to both the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index, marking its inclusion in two widely followed biotechnology benchmarks. This dual index entry can broaden Bicara’s visibility among institutional and index-tracking investors, potentially increasing liquidity and deepening market participation in the stock. Next, we’ll explore how Bicara’s new inclusion in major biotechnology indices may influence its...